In a deal that further underscores the growing importance of diagnostics, GE and Eli Lilly have signed a three-year agreement to study the pharmacological effects of a wide range of cancer drugs and develop in vitro diagnostic tests based on their findings. The companies hope to create tests that predict cancer treatment response to targeted therapies so that physicians can make informed decisions about which targeted therapies will be the most effective for patients.
"The combination of diagnostics and therapeutics is opening new doors in the fight against cancer and other life-threatening diseases. Through the application of molecular and cell biology to understanding disease, we can provide pharmaceutical companies with more advanced tools to develop more optimal drug therapies for cancer patients," said Dr. Michael Montalto, head of Molecular Imaging and Diagnostics Advanced Technologies for Global Research.
- see this release [1]Â for more
Related Articles:
Drug, diagnostic combos are the future. Report [2]
Personalized medicine advances with new genetic test. Report [3]
GE, Abbott call off $8.1B diagnostics deal. Report [4]
GE negotiating for Abbott diagnostics unit. Report [5]
JPMorgan, GE make healthcare acquisitions. Report [6]
Links:
[1] http://www.pharmalive.com/News/index.cfm?articleid=479997
[2] http://www.fiercepharma.com/story/drug-diagnostic-combos-are-future/2007-09-26
[3] http://www.fiercebiotech.com/story/personalized-medicine-advances-with-new-genetic-test/2007-02-07
[4] http://www.fiercebiotech.com/story/ge-abbott-call-8-1b-diagnostics-deal/2007-07-13
[5] http://www.fiercebiotech.com/story/ge-negotiating-for-abbott-diagnostics-unit/2007-01-18
[6] http://www.fiercehealthcare.com/story/jpmorgan-ge-make-healthcare-acquisitions/2007-01-18